Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses

J Control Release. 2023 May:357:310-318. doi: 10.1016/j.jconrel.2023.04.004. Epub 2023 Apr 6.

Abstract

Dendritic cells (DCs), the primary antigen-presenting cells in the immune system, play a critical role in regulating tumor immune responses. However, the tumor immunosuppressive microenvironment severely impedes the process of antigen-presenting and DC maturation, thereby limiting the efficacy of cancer immunotherapy. In this work, a pH-responsive polymer nanocarrier (PAG) modified with aminoguanidine (AG) was constructed for the efficient delivery of bortezomib (BTZ) through bidentate hydrogen bonds and electrostatic adsorption formed between guanidine groups of PAG and boronic acid groups of BTZ. The obtained PAG/BTZ nanoparticles exhibited pH-responsive release of BTZ and AG in the acidic tumor microenvironment. On the one hand, BTZ induced potent immune activation by eliciting immunogenic cell death (ICD) and releasing damage-associated molecular patterns. On the other hand, the cationic AG significantly promoted antigen uptake by DCs and activated DC maturation. As a result, PAG/BTZ significantly stimulated tumoral infiltration of cytotoxic T lymphocytes (CTLs) and triggered robust antitumor immune responses. Thus, it showed potent antitumor efficacy when synergizing with an immune checkpoint-blocking antibody.

Keywords: Aminoguanidine; Bortezomib; Cancer drug delivery; Chemo-immunotherapy; Immune activation; Immunogenic cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens
  • Bortezomib / pharmacology
  • Cell Line, Tumor
  • Drug Carriers / chemistry
  • Guanidine
  • Humans
  • Immunity
  • Immunotherapy
  • Nanoparticles* / chemistry
  • Neoplasms* / drug therapy
  • Tumor Microenvironment

Substances

  • Bortezomib
  • Drug Carriers
  • Guanidine
  • Antigens